Fig. 5: Antitumour effects of XCL1-OT-I. | British Journal of Cancer

Fig. 5: Antitumour effects of XCL1-OT-I.

From: Anticancer effects of chemokine-directed antigen delivery to a cross-presenting dendritic cell subset with immune checkpoint blockade

Fig. 5: Antitumour effects of XCL1-OT-I.The alternative text for this image may have been generated using AI.

a C57BL/6J mice were unimmunised (PBS) or immunised with OT-I peptide, OVA protein or XCL1-OT-I plus poly(I:C) on 14 and 7 days before inoculation of B16-OVA. b C57BL/6J mice were inoculated with B16-OVA and unimmunised (PBS) or immunised with OT-I peptide, OVA protein or XCL1-OT-I plus poly(I:C) on 7 and 14 days after the inoculation of B16-OVA. c β2m-deficient mice were unimmunised (PBS) or immunised with XCL1-OT-I plus poly(I:C) on 14 and 7 days before inoculation of B16-OVA. d β2m-deficient mice were inoculated with B16-OVA and unimmunised (PBS) or XCL1-OT-I plus poly(I:C) on 7 and 14 days after the inoculation of B16-OVA. e XCR1-deficient (Xcr1venus/venus) mice were unimmunised (PBS) or immunised with XCL1-OT-I plus poly(I:C) on 14 and 7 days before inoculation of B16-OVA. f XCR1-deficient (Xcr1venus/venus) mice were inoculated with B16-OVA, and unimmunised (PBS) or immunised with XCL1-OT-I plus poly(I:C) on 7 and 14 days after inoculation of B16-OVA. a, c, e The prophylactic model. b, d, f The therapeutic model. Tumour volumes were calculated at indicated days (n = 5 for each group). Similar data were obtained from one or two independent experiments. *p < 0.05, with ANOVA test. n.s., not significant. s.c., subcutaneously.

Back to article page